Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Other Non-Current Liabilities (2023 - 2026)

Prelude Therapeutics' Other Non-Current Liabilities history spans 4 years, with the latest figure at $2.8 million for Q1 2026.

  • On a quarterly basis, Other Non-Current Liabilities fell 8.22% to $2.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $2.8 million, a 8.22% decrease, with the full-year FY2025 number at $2.8 million, down 8.06% from a year prior.
  • Other Non-Current Liabilities hit $2.8 million in Q1 2026 for Prelude Therapeutics, down from $2.8 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for PRLD hit a ceiling of $3.3 million in Q4 2023 and a floor of $2.8 million in Q1 2026.
  • Historically, Other Non-Current Liabilities has averaged $3.1 million across 4 years, with a median of $3.1 million in 2024.
  • Biggest five-year swings in Other Non-Current Liabilities: decreased 7.46% in 2024 and later decreased 8.22% in 2026.
  • Tracing PRLD's Other Non-Current Liabilities over 4 years: stood at $3.3 million in 2023, then dropped by 7.46% to $3.1 million in 2024, then decreased by 8.06% to $2.8 million in 2025, then decreased by 2.18% to $2.8 million in 2026.
  • Business Quant data shows Other Non-Current Liabilities for PRLD at $2.8 million in Q1 2026, $2.8 million in Q4 2025, and $2.9 million in Q3 2025.